E-submission
Search
- Page Path
- HOME > Search
Original Articles
- Expression of c-kit and Cell Cycle Regulators in Non-small Cell Lung Carcinoma.
- Sun Hee Chang, Mee Joo, Hanseong Kim
- Korean J Pathol. 2006;40(6):427-431.
- 1,783 View
- 15 Download
-
Abstract
PDF - BACKGROUND
The abnormal expression of c-kit is implicated in the pathogenesis of a variety of solid tumors. The Rb pathway and p53 act as cell cycle regulators. The purpose of this study was to assess the expression of c-kit, Rb, p53, p16 and cyclin D1 and their relationship to clinical and pathological parameters in patients with non-small cell lung carcinomas (NSCLC(s)).
METHODS
Tissue microarrays consisting of 2 mm cores from the corresponding blocks were constructed from 54 NSCLC(s). Immunohistochemical staining for c-kit, Rb, p53, p16 and cyclin D1 was performed. C-kit immunostaining was considered positive if > or =10% of tumor cells were immunoreactive along the membrane and/or in cytoplasm. For Rb, p53, p16 and cyclin D1, tumor cells showing a nuclear staining pattern were interpreted as positive.
RESULTS
We found that c-kit was expressed in 13 (24%) cases, Rb was lost in 39 (72%) cases, p53 was expressed in 28 (52%) cases, p16 was lost in 42 (78%) cases and cyclin D1 was expressed in 33 (61%) cases. The c-kit expression was significantly higher in adenocarcinoma (39%) than in squamous cell carcinoma (8%). We did not find any correlation between c-kit, Rb, p53, p16 and cyclin D1 expression and clinicopathological parameters such as: age, tumor size, lymph node involvement, disease stage and distant metastasis. There was a direct correlation between p53 expression and Rb loss.
CONCLUSIONS
These results suggest that c-kit may be a useful therapeutic target for patients with c-kit positive tumors, and that the disruption of Rb and p53 pathways may play an important role in the development and progression of NSCLC(s).
- Significance of Galectin-3 Expression in Pulmonary Non-Small Cell Carcinoma.
- Dong Hoon Shin, Chang Hun Lee, Hyun Jung Kang, Mee Young Sol, Min Ki Lee
- Korean J Pathol. 2006;40(5):326-332.
- 1,697 View
- 18 Download
-
Abstract
PDF
- BACKGROUND
Non-small cell carcinoma (NSCC) has become the leading cause of cancer related death around the world. However, its prognostic factors remain poorly defined. Galectin-3 is an apoptosis related protein and its relationship with various cancers is presently the subject of research. This study was performed to investigate galectin-3 expression in NSCC and its value as a prognostic factor. METHODS: We examined the expression of galectin-3 and bcl-2 in surgically resected, lung NSCC, including 61 squamous cell carcinomas and 41 adenocarcinomas. PCNA staining was also performed. RESULTS: Each type of carcinoma showed cytoplasmic positivity in 18 (30.0%) and 25 (61.0%) cases, respectively. Squamous cell carcinoma showed increased galectin-3 expression in better differentiated tumors, whereas adenocarcinoma didn't show any relationship with the degree of differentiation. The cytoplasmic positivity of galectin-3 in both types of carcinoma was associated with poor prognosis. Bcl-2 expression didn't show any significant relationship with overall survival. Galectin-3 and bcl-2 expressions were positively correlated. However, co-expression of both proteins was not related to prognosis. CONCLUSIONS: These results indicate that galectin-3 expression in NSCC warrants attention as a possible prognostic factor.
- Clinicopathologic Significance of CD44s, CD44v5 and CD44v6 Expression in Non Small Cell Lung Carcinomas.
- Jae Kyun Kim, Chang Hun Lee, Kyeong Min Lee, Jin Mi Song
- Korean J Pathol. 2004;38(2):93-99.
- 1,598 View
- 12 Download
-
Abstract
PDF
- BACKGROUND
CD44 is a polymorphic family of transmembrane glycoproteins generated by alternative splicing of messenger RNA and is involved in the mechanism of tumor invasion and metastasis.
METHODS
The expression of selected CD44 molecules (CD44s, CD44v5, and CD44v6) was determined immunohistochemically in 84 cases of non small cell lung carcinomas (NSCLCs). The results were compared with PCNA index, microvessel density (MVD), and clinicopathological parameters including patient? survival.
RESULTS
CD44s showed a positive reaction in 61.9% (52/84) of NSCLCs, CD44v5 in 73.8% (62/84), and CD44v6 in 39.3% (33/84). Squamous cell carcinomas (SCCs) displayed preferential expression of all CD44 molecules in comparison with adenocarcinomas (ACs) (p<0.001). As a whole, the expression of CD44 molecules was not correlated with clinical parameters (stage, TNM-T, and TNM-N), PCNA index, or MVD. For ACs only, however, CD44v5 expression was negatively correlated with PCNA index (p<0.05). Poor survival was correlated with CD44v5 expression in ACs and CD44v6 in SCCs (both, p<0.05).
CONCLUSIONS
These findings suggest that CD44 molecule in NSCLC could be a distinctive phenotypic marker for SCC, and the possibility that CD44v5 and CD44v6 are in some way instrumental in conditioning the biologic behavior of NSCLC according to major histologic types.
First
Prev
